Why These 15 Stocks Are Skyrocketing in 2025

8. BridgeBio Pharma (NASDAQ:BBIO)

Number of Hedge Fund Holders In Q3 2024: 46

BridgeBio Pharma (NASDAQ:BBIO) is a biopharma company that makes treatments for genetic disorders. It has programs for cardiomyopathy, muscular dystrophy, skeletal dysplasias, gene therapy, and more.

BBIO stock has risen sharply so far in 2025 due to it receiving FDA approval for its leading drug called acoramidis, which is now branded as Attruby. It treats transthyretin amyloid cardiopathy (ATTR-CM). This approval took effect in late 2024. The commercial uptake so far seems to be strong, and BridgeBio disclosed that 430 prescriptions were written by 248 unique physicians. Moreover, the drug is being adopted at both academic centers and community sites.

In addition, early demand seems pretty solid. They also see three other Phase 3 trials in advanced stages, and these trials target conditions like limb-girdle muscular dystrophy type 2I/R9, autosomal dominant hypocalcemia type 1, and achondroplasia, so there is broad potential for additional approvals in 2025.

BridgeBio ended its last quarter with about $406 million cash on hand. It then secured “up to $1.25 billion of capital” from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis.

The average analyst price target on the stock is at $50.6, implying 37% upside potential.

BBIO stock is up 31.2% year-to-date.